MOTS-C 10mg
R850,00
MOTS-C 10mg is a mitochondrial-derived research peptide studied for tissue repair, inflammation modulation and regenerative biology in laboratory settings.
For Research Use Only
This product is not for human consumption.
By purchasing, you confirm that you agree to our Terms & Conditions.
MOTS-C 10mg — Research Overview
MOTS-C 10mg is a mitochondrial-derived peptide studied in preclinical research for its potential regenerative effects on muscle, soft tissue and cellular repair mechanisms. In laboratory settings, it is of particular interest for its role in metabolic regulation and inflammatory pathway modulation. This compound is supplied by ReGen-X exclusively for scientific and laboratory research.
Mechanism of Action (Research Context)
In controlled research environments, MOTS-C has been observed to influence the following pathways:
- Tissue regeneration — studied for its role in muscle and soft tissue repair in preclinical models
- Inflammatory modulation — associated with downregulation of oxidative stress and inflammatory signalling
- Cellular repair signalling — influences mitochondrial function and cellular energy pathways
Research Summary
MOTS-C has been evaluated in laboratory and experimental models for its potential role in:
- Tissue and muscle regeneration research
- Anti-inflammatory and recovery mechanisms
- Mitochondrial function and metabolic regulation
- Experimental regenerative biology studies
Browse our full range of Physical Recovery & Regeneration research compounds.
Product Specifications
- Compound: MOTS-C 10mg
- Quantity: 10mg
- Form: Lyophilised research peptide
- Included: 3ml bacteriostatic water (for laboratory reconstitution only)
- Storage: Refrigerated per laboratory standards
Important Research Use Notice
This product is sold strictly for laboratory and scientific research use only. It is not a medicine, not a supplement, and not approved for human or veterinary use. No medical, therapeutic, or health claims are made or implied.






Reviews
There are no reviews yet.